Iqirvo (Elafibranor)

Elafibranor activates the nuclear receptors PPARα and PPARδ, which regulate genes involved in lipid metabolism, inflammation, and fibrogenesis. By stimulating these receptors, the drug promotes fatty‑acid oxidation, lowers inflammatory cytokine production, and interferes with pathways that lead to liver scarring, thereby supporting healthier liver tissue.

The dose of Iqirvo is determined by the prescribing clinician based on the individual patient's clinical status, liver function, and other relevant factors. Healthcare professionals tailor the regimen to achieve optimal therapeutic effect while monitoring safety, and patients should follow the prescriber’s specific instructions.

Safety of elafibranor in pregnancy and lactation has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Iqirvo product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including any cold‑chain needs), and assists with import documentation.

The primary approved therapy for primary biliary cholangitis is ursodeoxycholic acid (UDCA). While UDCA improves bile flow and liver enzymes, elafibranor targets metabolic and inflammatory pathways through PPAR activation, offering a complementary mechanism that may benefit patients with an inadequate response to UDCA. Clinical decisions depend on individual disease severity and response.

Iqirvo should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not store in areas with high humidity or direct sunlight, and ensure the container remains tightly closed when not in use.

Iqirvo is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. Patients should swallow the dose whole with a full glass of water and follow any specific timing instructions provided by their healthcare professional.

Serious risks include significant elevations in liver enzymes indicating possible hepatic injury, severe allergic reactions such as anaphylaxis, and rare cases of hepatic decompensation or pancreatitis. Patients should be monitored regularly for signs of liver dysfunction, rash, swelling, or abdominal pain, and report any concerning symptoms promptly.

Iqirvo is contraindicated in individuals with known hypersensitivity to elafibranor or any of its excipients. It should also be avoided in patients with severe liver impairment, uncontrolled cardiovascular disease, or those taking medications that have a major interaction risk without appropriate monitoring. Clinicians must assess each patient’s medical history before prescribing.